Kyowa Kirin International
CompanyUnited Kingdom
Kyowa Kirin International develops one asset. Mostly antibody acting on CCR4; based in the United Kingdom.
- 1
- Asset
- Furthest stage
- Not known
- 0
- Trials
- 1
- Signal
Pipeline
1Binds CCR4 on malignant T cells and induces antibody-dependent cellular cytotoxicity.
Stage not known, Antibody, CCR4
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals1